ReviewAbdominal radiology (New York)2026
The bulging pancreas: unmasking causes beyond autoimmunity-an imaging-based approach to diffuse pancreatic enlargement.
Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse pancreatic enlargement is frequently attributed to autoimmune pancreatitis (AIP), but several benign, genetic, inflammatory, including acute interstitial edematous pancreatitis, and malignant entities can produce a similar imaging appearance. This review provides an imaging-based approach to recognize diffuse pancreatic enlargement, apply pragmatic measurement rules, and differentiate AIP from key mimics. Classic AIP imaging features (diffuse "sausage-like" morphology, capsule-like rim, long-segment duct narrowing without marked upstream dilation) and the value of clinical/serologic correlation and steroid response are emphasized. Key mimics reviewed include acute interstitial edematous pancreatitis, pancreatic lipomatosis, von Hippel-Lindau (VHL) disease, Mahvash syndrome, infiltrative adenocarcinoma, lymphoma, metastases, and diffuse neuroendocrine tumor, each with discriminating imaging and clinical clues. A structured assessment combining objective measurement, duct evaluation, enhancement pattern, systemic findings, and response to therapy after pancreatic malignancy has been reasonably excluded can reduce misdiagnosis of diffuse pancreatic enlargement and expedite appropriate biopsy or oncologic workup when indicated.
Indexed as
Identifiers
42541553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.